Nicholas N. Smithers

Stevenage, ENG SG12FX, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn's Disease.

A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn's Disease.

Journal: Cells

Published: June 15, 2022

Bromodomain Inhibitors Modulate FcγR-Mediated Mononuclear Phagocyte Activation and Chemotaxis.

Bromodomain Inhibitors Modulate FcγR-Mediated Mononuclear Phagocyte Activation and Chemotaxis.

Journal: Frontiers in immunology

Published: February 27, 2022

Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate.

Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate.

Journal: Journal of medicinal chemistry

Published: January 07, 2022

Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.

Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.

Journal: Journal of medicinal chemistry

Published: August 13, 2021

Brd2/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation in vitro.

Brd2/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation in vitro.

Journal: iScience

Published: October 02, 2020

Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia.

Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia.

Journal: Blood advances

Published: June 14, 2019

Bromodomain inhibitor I-BET151 suppresses immune responses during fungal-immune interaction.

Bromodomain inhibitor I-BET151 suppresses immune responses during fungal-immune interaction.

Journal: European journal of immunology

Published: January 04, 2019

Inhibition of BET Proteins Reduces Right Ventricle Hypertrophy and Pulmonary Hypertension Resulting from Combined Hypoxia and Pulmonary Inflammation.

Inhibition of BET Proteins Reduces Right Ventricle Hypertrophy and Pulmonary Hypertension Resulting from Combined Hypoxia and Pulmonary Inflammation.

Journal: International journal of molecular sciences

Published: July 05, 2018

Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL.

Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL.

Journal: Molecular cancer therapeutics

Published: November 13, 2017

Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins.

Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins.

Journal: Scientific reports

Published: May 23, 2017

Selective inhibition of BET proteins reduces pancreatic damage and systemic inflammation in bile acid- and fatty acid ethyl ester- but not caerulein-induced acute pancreatitis.

Selective inhibition of BET proteins reduces pancreatic damage and systemic inflammation in bile acid- and fatty acid ethyl ester- but not caerulein-induced acute pancreatitis.

Journal: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]

Published: December 23, 2016

TLR4 signals in B lymphocytes are transduced via the B cell antigen receptor and SYK.

TLR4 signals in B lymphocytes are transduced via the B cell antigen receptor and SYK.

Journal: The Journal of experimental medicine

Published: July 15, 2016

Showing 1-12 of 23

Last Updated: 09/26/2026